Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-assisted psychotherapy for posttraumatic stress disorder
ACTRN12623000838617Phase 2Active, not recruiting
- Sponsor
- Emyria Ltd
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by Emyria Ltd. Primary endpoints: Safety and tolerability and Feasibility of delivery in Australia. Started Jul 2023; status: active, not recruiting.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on ACTRN12623000838617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000838617.